Jake Baker
LightNews LightNews
jakebakermd.bsky.social
Jake Baker
@jakebakermd.bsky.social
1.1K followers 1.5K following 23 posts
ID doc at a community hospital in West Michigan, recovering MD/PhD (abramovitchlab, TB genetics and metabolism) with a soft spot for research, public health, and HIV.
Posts Replies Media Videos
Pinned
jakebakermd.bsky.social
Jake Baker @jakebakermd.bsky.social · Nov 20
Alright #IDSky, #HIVSky, let’s get talking. I have some questions about the RePRIEVE trial. I’ve been mulling over the results, and have a few potential critiques* that come from a place of genuine curiosity. Hoping for some discussion; particularly if you think I missed something.
Reposted by Jake Baker
paulsaxmd.bsky.social
The University of Washington's National HIV Curriculum, headed by Dr. David Spach, is one of the best on-line resources for HIV information anywhere.

I refer people to it *all the time*.

Really hoping valuable resources like this are up and running again soon. #IDSky
www.hiv.uw.edu
Notification at this web site.
February 3, 2025 at 10:01 PM
Reposted by Jake Baker
brainofbpharm.bsky.social
Ceftriaxone FTW as empiric GNR coverage! No increased risk of harm to patients who had escalation of ABX therapy. #IDSky
academic.oup.com/cid/advance-...
Association between Delayed Broad-Spectrum Gram-negative Antibiotics and Clinical Outcomes: How Much Does Getting It Right with Empiric Antibiotics Matter?
Empiric antibiotics are frequently unnecessarily broad-spectrum. This study compared clinical outcomes between matched patients who received early vs. dela
academic.oup.com
January 31, 2025 at 9:59 PM
Reposted by Jake Baker
sebpoule.bsky.social
Potential impact of increasing CAB/RPV use on the future efficacy of INSTIs as first-line therapy for HIV.

#IDsky #HIVsky

@cidjournal.bsky.social

academic.oup.com/cid/advance-...
Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: A meta-analysis
Although 48-week virological failure rates were low, emergent integrase resistance among those failing injectable cabotegravir was common (41-71%), and cro
academic.oup.com
January 6, 2025 at 12:47 AM
Reposted by Jake Baker
takamatsuo-id.bsky.social
【Mayo Clinic CME Orthopedic Infectious Diseases 2025】

👉Comprehensive #OrthoID learning course is coming soon!

👉Great learning opportunity for #IDFellow #IMResident #OrthoResident!

ce.mayo.edu/orthopedic-s...

#IDMedEd #IDFellow #OrthoID #MayoClinicINFD #MSIS #EBJIS
December 31, 2024 at 1:41 AM
Reposted by Jake Baker
absteward.bsky.social
🆕🔥Just published 🔥🆕
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis(TB)
An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline #idsky #TBsky
www.atsjournals.org/doi/full/10....
January 2, 2025 at 6:53 PM
Reposted by Jake Baker
absteward.bsky.social
🆕💫“Weight and See”: Initial Weight Gain After Starting Antiretroviral Therapy Is Not Associated With Antiretroviral Regimen Type And Does Not Predict Subsequent Weight Trajectory #idsky #hivsky
academic.oup.com/ofid/advance...
“Weight and See”: Initial Weight Gain After Starting Antiretroviral Therapy Is Not Associated With Antiretroviral Regimen Type And Does Not Predict Subsequent Weight Trajectory
Abstract. In a Canadian HIV cohort, 61% gained/26% lost/12% stable weight in the first year of antiretroviral therapy (ART). Weight gain was not associated
academic.oup.com
January 2, 2025 at 7:20 PM
Reposted by Jake Baker
cortes-penfield.bsky.social
The cutoff for what constitutes “Acute PJI” is inconsistently (and somewhat arbitrarily) defined, but this recent cohort study of >5000 DAIR procedure out of Australia suggests that treatment outcomes deteriorate when DAIR is performed more than 4wk postoperatively

pubmed.ncbi.nlm.nih.gov/39710215/
Outcomes of Debridement, Antibiotics, and Implant Retention in the Management of Infected Total Knee Arthroplasty: Analysis of 5,178 Cases from the National Australian Registry - PubMed
These findings underscore the critical influence of patient-related factors and the timing of DAIR treatment on the need for additional surgery. DAIR after four weeks had an increased risk of subseque...
pubmed.ncbi.nlm.nih.gov
December 23, 2024 at 11:33 PM
Reposted by Jake Baker
aliciadwright.bsky.social
“… rats have detected #Tuberculosis but follow up clinical tests have been negative; in some of these cases, patients later developed TB... Apopo is monitoring these patients to better understand rats’ sensitivity to low levels of bacteria”.
www.theguardian.com/global-devel...
Cheap, smart and efficient: how giant rats are transforming the fight against TB
After success in Tanzania, other African countries may introduce the rodents to help sniff out the disease
www.theguardian.com
December 19, 2024 at 1:04 PM
Reposted by Jake Baker
rolandoug.bsky.social
Ayer el #CDC reportó el 1er caso confirmado en 🇺🇸 de enfermedad severa por influenza A aviar H5N1 #birdflu en humanos. Desde Abril 2024: 61 casos en humanos en USA. Hasta ahora transmisión entre humanos NO se ha demostrado. #idsky #pedsidsky Link:
www.cdc.gov/media/releas...
December 20, 2024 at 1:47 AM
Reposted by Jake Baker
umn-idim.bsky.social
Spinal implant infections are a serious complication of fusion surgeries. Our faculty member, Dr. Tai, is advancing understanding of their diagnosis and management, focusing on the key differences between early and chronic infections. #IDSky
academic.oup.com/cid/article/...
Educational graphic
December 18, 2024 at 12:44 PM
Reposted by Jake Baker
science.org
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.

Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. The drug attaches to the lattice-like capsid proteins that shield the virus’s genetic material—a mechanism that could inspire other antivirals. Lenacapavir could help end the HIV/AIDS epidemic, but that will hinge on access for those who need it most.
December 12, 2024 at 7:02 PM
Reposted by Jake Baker
jakebakermd.bsky.social
Alright #IDSky, #HIVSky, let’s get talking. I have some questions about the RePRIEVE trial. I’ve been mulling over the results, and have a few potential critiques* that come from a place of genuine curiosity. Hoping for some discussion; particularly if you think I missed something.
November 20, 2024 at 6:18 PM
Reposted by Jake Baker
drtimothyli.bsky.social
Flat dosing of pyrazinamide at 1000mg achieved a higher proportion of participants within the therapeutic window compared with weight-banded dosing and flat dosing at 1500mg

Has anyone already switched to flat dosing of pyrazinamide at 1000mg/day for TB?

doi.org/10.1164/rccm...

#IDSky
#TBSky
November 30, 2024 at 2:36 PM
Reposted by Jake Baker
calderwoodmd.bsky.social
Across 14 studies with ~21k patients, PICC lines had a two-fold higher risk of bloodstream infection than midlines, but midlines had higher rates of superficial vein thrombosis, infiltrations, and leaks. PICCs are higher cost and have higher patient dissatisfaction. www.cambridge.org/core/journal...
Which is the safer option for adult patients between peripherally inserted central catheters and midline catheters: a meta-analysis | Infection Control & Hospital Epidemiology | Cambridge Core
Which is the safer option for adult patients between peripherally inserted central catheters and midline catheters: a meta-analysis
www.cambridge.org
November 22, 2024 at 3:30 AM
Reposted by Jake Baker
absteward.bsky.social
🔥BALANCE RCT🔥
74 hospitals in 7 countries
3,608 patients
A 7-day course of antibiotics for hospitalized patients with bloodstream infections was non inferior to 14d within a 4% prespecified margin for mortality at 90 days #idsky
www.nejm.org/doi/full/10....
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM
Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...
www.nejm.org
November 20, 2024 at 1:07 PM
jakebakermd.bsky.social
Alright #IDSky, #HIVSky, let’s get talking. I have some questions about the RePRIEVE trial. I’ve been mulling over the results, and have a few potential critiques* that come from a place of genuine curiosity. Hoping for some discussion; particularly if you think I missed something.
November 20, 2024 at 6:18 PM
Reposted by Jake Baker
gpollara.bsky.social
The really scary aspect of this study below is that all these cefiderocol resistant isolates were from people with NO exposure to cefiderocol!!!

#AMR #IDSky
November 18, 2024 at 10:58 AM
Reposted by Jake Baker
docdelrio.bsky.social
The selection of RFK Jr as HHS Secretary creates for me an others in Inf Diseases a situation of unknown unknowns where risks will come from situations that are so unexpected that we have never even considered them.
November 15, 2024 at 3:17 PM
jakebakermd.bsky.social
Hi #IDSky, #MedSky
I joined X late enough in the game that it wasn’t worth more than lurking in the shadows for the new publication updates. Appreciate the optimism and not-bots feel over here already.
November 12, 2024 at 12:21 PM